期刊
HUMAN VACCINES & IMMUNOTHERAPEUTICS
卷 18, 期 1, 页码 -出版社
TAYLOR & FRANCIS INC
DOI: 10.1080/21645515.2021.1883379
关键词
Bronchiolitis; respiratory syncytial virus; epidemiology; Spain; vaccine; immunotherapy; children
资金
- Sanofi
Bronchiolitis is a significant burden in children under 2 years of age in Spain, with over 100,000 hospitalizations and 82 deaths reported from 2012 to 2017. Most cases requiring hospitalization were in infants under 3 months of age, and the annual average cost to the National Health Care System was euro58 million.
Bronchiolitis represents a heavy burden of disease in children under 2 years of age in our society due to the high infectivity of the Respiratory Syncytial Virus [RSV] and the vulnerability of the youngest children. The objective of this retrospective epidemiological study was to show the burden of severe bronchiolitis in Spain through population-based estimates of hospitalizations due to bronchiolitis in children up to 24 months old during a 6-year period (2012-2017). A total of 100,115 cases of bronchiolitis required hospitalization in Spain from 2012 to 2017. Most cases of bronchiolitis that required hospitalization were in infants under 3 months of age. The hospitalization rate for bronchiolitis for children under 1 year of age was 3,838.27 per 100,000 healthy children. During the 6-year study period, a total of 82 deaths due to bronchiolitis were reported among hospitalized infants. Among these deaths, more than 50% were in patients younger than 3 months of age. The annual average cost to the National Health Care System was euro58 M, with a mean hospitalization cost of euro3,512 per case.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据